In December, Verona will participate in fireside chats at Piper Sandler's 36th Annual Healthcare Conference and the Evercore ISI HealthCONx Conference. Learn more about our recent product launch and future plans. Join us at Piper here: https://bit.ly/3V83eUu and Evercore here: https://bit.ly/3ZnMVW3
Verona Pharma
Biotechnology Research
London, UK 15,997 followers
Developing life enhancing treatments for chronic respiratory diseases
About us
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma's product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Ensifentrine met the primary endpoint in both ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in lung function. In addition, ensifentrine significantly reduced the rate of COPD exacerbations in ENHANCE-1 and ENHANCE-2. We are led by a management team with an established track record in the discovery, development and commercialization of respiratory therapies. Verona Pharma is listed on the Nasdaq Global Market in the United States under the ticker symbol VRNA. We are headquartered in London, UK, and have offices in Raleigh and Savannah in the US. For more information, please visit https://www.veronapharma.com.
- Website
-
https://www.veronapharma.com
External link for Verona Pharma
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- London, UK
- Type
- Public Company
- Founded
- 2005
- Specialties
- Novel therapies for chronic respiratory diseases , COPD, CF, and Asthma
Locations
-
Primary
Get directions
3 More London Riverside
London, UK SE1 2RE, GB
-
Get directions
8045 Arco Corporate Drive
Suite 130
Raleigh, North Carolina 27617, US
-
Get directions
33 Park of Commerce Way
Savannah, Georgia 31405, US
Employees at Verona Pharma
Updates
-
Wednesday was #WorldCOPDDay, a day dedicated to raising awareness, sharing knowledge, and discussing ways to reduce the burden of #COPD on the millions of patients and caregivers around the globe. Our team came together to celebrate the strides we’ve made in COPD treatment innovation. Learn more: https://bit.ly/3YVhscu
-
-
On #WorldCOPDDay, we join the global community in raising awareness of #COPD, a chronic lung disease affecting millions of people worldwide. COPD is often underdiagnosed and undertreated, making it crucial to promote disease awareness and patient resources. Together, we can help those living with COPD breathe easier. Discover patient resources here: https://bit.ly/3YJ4gZT
-
-
Tomorrow, Verona’s management team will be attending the Jefferies London Healthcare Conference. We look forward to discussing our recently launched therapy in the US and our ongoing work to advance respiratory care. Listen to our fireside chat here: https://bit.ly/40lXo5v
-
-
We’re pleased to partner with the Global Initiative for Chronic Obstructive Lung Disease as a Sponsor of the 9th annual GOLD International COPD Conference in Philadelphia – the world’s largest educational symposium on #COPD. We support GOLD in its mission to improve the lives of patients with COPD by raising awareness and improving prevention and treatment of this lung disease. #GOLDCOPD2024
-
-
Today, we announced our financial results for the third quarter, which ended September 30, 2024. We continue to see strong momentum in bringing our first commercial product to patients in need. Join us for the webcast later today to learn more about our progress and future plans: https://bit.ly/3UASkGE
-
-
This November, during #COPDAwarenessMonth, we stand with the millions of families affected by #COPD. It’s vital to understand the symptoms, risks, and treatment options for improving the lives of those living with this challenging condition. Let's work together to increase awareness, promote use of innovative treatments, and support those battling COPD every day. Discover patient resources here: https://bit.ly/3YJ4gZT
-
-
We are excited to share that Verona Pharma is a finalist for the #FierceInnovationAwards in the Biotech Innovation category. This award highlights forward-thinking products and services that have the greatest potential to make a big impact on the biotech industry. We are committed to bringing innovative treatments to patients with #COPD and other respiratory diseases. #FierceLifeSciencesAwards
-
-
This week is Respiratory Care Week, and we want to thank #respiratory healthcare professionals and caregivers who focus their expertise on keeping the lungs of patients with COPD as healthy as possible. #RCWeek24 #COPD
-
-
In two weeks, we will announce our financial results for Q3 2024, ended September 30, 2024. Tune into our webcast on Monday, November 4th at 9:00 a.m. EST / 2:00 p.m. GMT UK: https://bit.ly/3Yge8Ir #COPD
-